Expert Review of Clinical Pharmacology, published by TAYLOR & FRANCIS LTD, is a leading peer-reviewed journal dedicated to the field of clinical pharmacology, with a strong focus on the development and application of pharmacological therapies in patient care. Boasting an impressive impact, the journal ranks in the first quartile across multiple categories including Medicine (miscellaneous), Pharmacology (medical), and Pharmacology, Toxicology and Pharmaceutics (miscellaneous), reflecting its influential position within the scientific community. With a Scopus ranking of #6 in General Pharmacology, Toxicology and Pharmaceutics, the journal also achieves a commendable 93rd percentile, further emphasizing its importance as a resource for researchers and clinicians alike. As it continues to publish innovative reviews and research articles from 2008 until 2024, the Expert Review of Clinical Pharmacology plays an essential role in advancing knowledge, improving clinical practice, and fostering collaboration among experts in pharmacology, thereby driving forward the field's evolution towards better patient outcomes.

The American Journal of Psychiatry, published by the renowned American Psychiatric Publishing, Inc., stands as a premier platform in the field of Psychiatry and Mental Health. With its inaugural edition released in 1945, this esteemed journal has consistently provided a wealth of knowledge, shaping the landscape of psychiatric research and practice globally. Notably, in the latest 2023 Scopus rankings, it achieved an impressive rank of #7 out of 567 journals in its category, placing it in the top 2% percentile, indicative of its substantial impact within the field. The journal is committed to publishing high-quality, peer-reviewed original research, clinical studies, and reviews that advance psychiatric knowledge and treatment options. Although it does not currently offer open access, its contributions are vital for researchers, clinicians, and students dedicated to improving mental health care and understanding complex mental health disorders. As an essential resource, it continues to foster scholarly communication among professionals who are at the forefront of psychiatric science.

BIPOLAR DISORDERS, published by Wiley, is a leading international journal dedicated to advancing the understanding and treatment of bipolar disorders. Since its establishment in 1999, the journal has become a vital resource in the fields of Biological Psychiatry and Psychiatry and Mental Health, currently ranked in the Q2 category for Biological Psychiatry and Q1 for Psychiatry and Mental Health as of 2023. With impressive Scopus rankings, it stands at 75th out of 567 in Psychiatry and Mental Health and 11th out of 51 in Biological Psychiatry, reflecting its influential role in shaping mental health research. The journal not only focuses on empirical studies, reviews, and clinical reports but also encourages innovative methodological advancements in understanding bipolar disorders. Although it does not offer Open Access, its extensive coverage from 1999 to 2024 ensures that practitioners, researchers, and students have access to a wealth of knowledge critical for the development of effective therapeutic interventions. For those engaging with cutting-edge research in psychiatric care, BIPOLAR DISORDERS serves as an essential platform for knowledge dissemination and academic discourse.

NEUROPSYCHOPHARMACOLOGY is a prestigious academic journal dedicated to advancing our understanding of the intricate relationship between psychiatric disorders and pharmacological treatments. Published by SpringerNature in the United Kingdom, this leading journal has been a cornerstone in the field since its inception in 1987, with a converged publication timeline extending to 2024. With a remarkable impact factor and illustrious rankings—being positioned 19th in Psychiatry and Mental Health and 16th in Pharmacology—NEUROPSYCHOPHARMACOLOGY is recognized for its rigorous peer-reviewed research that informs clinical practice and enhances therapeutic interventions. The journal is classified in Q1 quartile categories for both Pharmacology and Psychiatry and Mental Health, highlighting its commitment to excellence. Researchers, professionals, and students are encouraged to contribute to this vital dialogue, as the journal does not currently offer open access, emphasizing the importance of curated, high-quality content. By publishing innovative studies and reviews, NEUROPSYCHOPHARMACOLOGY plays a crucial role in shaping the future of mental health treatments and understanding neurobiological mechanisms, making it an indispensable resource for those at the forefront of psychiatric research.

PSYCHOPHARMACOLOGY is a leading peer-reviewed journal specializing in the field of pharmacology, specifically focusing on the effects of drugs on behavior, cognition, and emotion. Published by Springer, this esteemed journal has established itself as a pivotal resource for researchers and professionals since its inception in 1959, maintaining its relevance and rigor in the ever-evolving landscape of psychopharmacological research. With an impressive impact factor and ranking in the top quartile (Q1) of the Pharmacology category in 2023, it consistently publishes high-quality studies that contribute to both academic inquiry and clinical practice. The journal's scope includes original research, theoretical papers, and reviews, fostering a multidisciplinary dialogue among psychologists, psychiatrists, pharmacologists, and neuroscientists. As the field of psychopharmacology continues to grow, PSYCHOPHARMACOLOGY remains dedicated to disseminating innovative findings, operationalizing complex concepts, and enhancing the understanding of drug mechanisms and their implications for mental health. This commitment to excellence positions PSYCHOPHARMACOLOGY as an indispensable tool for those seeking to advance their knowledge and research in pharmacology.

Annals of Clinical Psychiatry, published by QUADRANT HEALTHCOM INC, is a leading journal in the fields of Medicine and Psychiatry & Mental Health. With its longstanding commitment to advancing clinical knowledge since 1989, this esteemed journal contributes invaluable insights into current psychiatric practices and mental health research. The journal is recognized in the Scopus ranking with a position in the 34th percentile, reflective of its focused scope and substantial academic contributions. While access to the journal is tailored for professionals and researchers, the absence of Open Access highlights the journal's dedication to maintaining quality and rigorous peer-reviewed standards. As part of the Q3 quartile for both Medicine and Psychiatry categories in 2023, Annals of Clinical Psychiatry serves as an essential resource for those dedicated to improving mental health outcomes, making it a vital platform for practitioners, researchers, and students alike. Situated in Parsippany, New Jersey, the journal remains a pivotal entity that fosters scholarly dialogue and exploration in clinical psychiatry.

PSYCHOLOGICAL MEDICINE is a leading journal in the field of psychiatry and psychology, published by Cambridge University Press. With its ISSN 0033-2917 and E-ISSN 1469-8978, this journal has firmly established itself as a premier platform for cutting-edge research since its inception in 1970. It consistently ranks in the top quartile for both Applied Psychology and Psychiatry and Mental Health, reflecting its exceptional impact in the field, with a 2023 Scopus ranking of #36 out of 567 in Psychiatry and Mental Health, and #21 out of 249 in Applied Psychology. The journal aims to publish comprehensive studies that explore the interplay between psychological phenomena and medical health, contributing vital insights that advance both theoretical understanding and clinical practice. Although it is not an Open Access journal, PSYCHOLOGICAL MEDICINE remains a vital resource for researchers, professionals, and students committed to the scientific investigation of mental health issues.

INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, published by Lippincott Williams & Wilkins, stands as a pivotal peer-reviewed journal in the fields of pharmacology and psychiatry. Established in 1986, it has garnered a prominent reputation with a 2023 impact factor placing it in the Q2 category for both Pharmacology and Psychiatry and Mental Health. With an impressive Scopus ranking of #227 in the Psychiatry and Mental Health category and #114 in Pharmacology, it serves as an essential platform for researchers seeking to disseminate critical findings on psychopharmacological interventions and their clinical efficacy. The journal’s rigorous peer-review process ensures that only high-quality research is published, making it a trusted resource for professionals and students alike. By focusing on the latest advancements and evidence-based practices, the INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY contributes significantly to the understanding of mental health treatments, fostering ongoing dialogue and innovation in the discipline.

Pharmakopsychiatry is a distinguished journal published by Georg Thieme Verlag KG that has been at the forefront of research since its inception in 1984. This peer-reviewed journal, with an ISSN of 0176-3679 and E-ISSN of 1439-0795, occupies a pivotal role in the field of medicine, focusing on the intricate intersections of pharmacology, psychiatry, and mental health. Its robust academic standing is demonstrated by its Q2 quartile rankings across multiple categories, including Medicine (miscellaneous) and Psychiatry and Mental Health, showcasing its significant influence with Scopus ranks placing it in the 80th percentile for Psychiatry and Mental Health. Pharmakopsychiatry aims to disseminate cutting-edge research that advances our understanding of pharmacological treatments in psychiatric practice, catering to a diverse audience of researchers, clinicians, and students. With an unwavering commitment to high-quality scholarship and its strategic location in Germany, this journal is an essential resource for those seeking to stay abreast of emerging trends and methodologies in the field.

JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, published by MARY ANN LIEBERT, INC, stands as a premier academic journal dedicated to advancing the field of pediatric psychopharmacology. With a rich history of publication spanning from 1990 to 2024, this journal presents cutting-edge research that informs clinical practices and policy decisions impacting the mental health of children and adolescents. Ranked in the Q2 category for both Pediatrics, Perinatology and Child Health and Pharmacology (medical) as of 2023, it reflects its critical contribution to these fields, along with a respectable Q3 status in Psychiatry and Mental Health. Researchers and practitioners benefit from the journal's rigorous peer-reviewed articles, which delve into the efficacy, safety, and ethical implications of pharmacological treatments tailored for young populations. Although the journal does not currently offer Open Access, it remains a vital resource for anyone engaged in child and adolescent health research and treatment strategies. Its commitment to fostering dialogue and innovation in psychopharmacology ensures its pivotal role in shaping future standards and practices in this essential area of medical science.